



## **RESULTS FOR THE FIRST QUARTER 2018**

- WITH THE SUPPORT OF INSERM, GET EUROPEAN FUNDS**
- LAST FUNDRAISES BEFORE CHANGING THE FUNDING MODEL**

**Arles, April 16, 2018** - CELL CONSTRAINT & CANCER, a company specializing in the treatment of pancreatic cancer with mechanical signals, presents its review of the past period, as well as its strategic priorities for the next quarter.

### **A DECISIVE PARTNERSHIP WITH INSERM TO FIND A NEW CURE FOR PANCREATIC CANCER**

The FET-Open call for projects, which is part of the Horizon 2020 program for research initiated by the European Commission, selects its laureates for their founding, transdisciplinary, breakthrough research objective. CC & C has been developing a solution for pancreatic cancer for several years based on the fundamentals of physical oncology. Today, in a consortium of teams from the Faculty of Medicine of Bichat (France), Universities of Mons (Belgium) and Patras (Greece), and under the patronage of INSERM (the French public research organization dedicated to health), the company is preparing to respond to this call. Other potential partners are still in talks to join the team, particularly in Germany. The budget, oscillating between 3 and 4 million euros spanning two years, would validate the original proposal (treat pancreatic cancer), but also open new avenues on other types of tumors. Appointment on May 15th for the filing of the file.

Obtaining these funds would mean for CC & C the end of financial uncertainty for a few years, the hiring of young researchers to participate in short-term experiments, and the assurance of finishing the research within two years. Considerable work has already been done, namely the drafting of the experimental protocol, and the consortium meeting.

Obtaining this budget would reward all the efforts made so far.

### **MAGNETIC FIELD GRADIENT GENERATORS: A TECHNOLOGY BETTER AND BETTER CONTROLLED**

Magnetic Insight, a Californian start-up, develops medical imaging solutions. They developed a magnetic field-gradient generator (MFGG) prototype and sold a copy to Stanford University. Other imaging companies have moved in this direction, including Phillips and Bruker, who have built several machines in Germany to develop powers of the order of 3 to 4 Tesla per meter.

After discussion with their manufacturers, we learned that we could fairly easily reconfigure these machines to serve therapeutic purposes. CC & C is currently in discussions with medical imaging companies to reuse their MFGG prototypes for our own research.

Recall that the economic model of CC & C is to finish its research (get its Proof of Efficacy) and then start the co-development of the human prototype with a medical imaging industry. The fact that discussions are initiated is therefore an excellent signal for the future.

### **2018: A LAST CALL FOR PRIVATE SAVINGS**

Calls for public funding are nonetheless random, and the company needs to ensure its good financial health to hope to interest investment funds or industrial companies after its research. It was therefore decided to make a last fundraising operation by capital increase. The sums collected will be used to

ensure a correct capital ratio, and if necessary, to conduct research without public funding. The operation aims to raise 250,000 euros. The CC & C site has been thoroughly renovated for the occasion, and now allows to invest online.

Go to <http://cellconstraintcancer.com/investors>

In 2 years, if the results of the Proof of Efficacy are in line with our expectations, the value of society will be multiplied if we believe the recent examples in immunology. This is an excellent transaction for investors.

## COMING FOR THE 2nd QUARTER OF 2018

CC & C is therefore involved in two calls for projects in Europe and the United States. The two deadlines are May 15th and June 15th. All the energies of the company will therefore be turned towards the writing of the files, in parallel with the fundraising operation.

In the process, we'll have to prepare the hiring of a young doctor and wait for the results of calls for projects.

Finally, the CEO and CSO of CC & C are expected for a trip to Stanford in the fall.

*"The change in pace over the last two years is surprising and delighting us. If we are confident in the scientific interest of our research, go through a process of call to project inevitably contains a degree of uncertainty. Having managed to build consortia with such prestigious partners as INSERM or Stanford University should obviously reassure juries." says Barthélemy BROSSEL, CEO of CELL CONSTRAINT & CANCER. "We are now looking forward to starting the actual research work and getting the results patients need."*

**Next appointment: June 30, 2018 - Update on Q2 2018 activity**

Find all the information on CELL CONSTRAINT & CANCER:

<http://new.cellconstraintcancer.com/>



## About CELL CONSTRAINT & CANCER

Founded in 2009 by Rémy BROSSEL, medical oncologist and physicist, CELL CONSTRAINT & CANCER develops innovative treatments based on [physical oncology](#), complementary to current approaches to oncology. Addressing primarily non-metastatic non-operable tumors, such as cancer of the pancreas, brain, or liver, the company published in May 2016 a proof of concept of slowing the growth of an in vivo grafted cancer tumor, by the action of mechanical signals (read our article: [Mechanical signals inhibit growth of a grafted tumor in vivo: Proof of Concept](#)).

The establishment of major partnerships (CNRS, INSERM, Stanford University) and the support of its shareholders since its beginning allow it today to initiate a new phase of experiments on animals intended to provide proof of the effectiveness of its technology on unmet medical needs.

## CONTACTS

Press Relations

Barthélemy BROSSEL

Tél. : +33 (0)6 50 22 79 64

Mail : [barth.brossel@gmail.com](mailto:barth.brossel@gmail.com)

Shareholders & Investors Relations

Christine GRAU

Tél. : +33 (0)4 90 18 48 50

Mail : [investisseurs@cellconstraintcancer.com](mailto:investisseurs@cellconstraintcancer.com)